Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data ...
MPR1d
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Stocktwits on MSN1d
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?
Shares of clinical-stage genetic medicine company Lexeo Therapeutics, Inc. soared over 50% on Monday, marking their best day ...
TCTMD1d
Some Mitral TEER Patients Slipping Through the Cracks in the First Month
Out-of-hospital mortality before 30 days was 1.2%, with roughly two-thirds of these patients dying from cardiovascular causes ...
TMCnet2d
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...
Zacks Investment Research on MSN2d
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
Heart4d
Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
Background Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience worsening cardiac disease (WCD) ...
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...
TCTMD4d
Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
Managed Healthcare Executive4d
FDA Approves Amvuttra for ATTR-CM in Extended Label
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
Healio4d
FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Physician's Weekly4d
Patient-Performed Functional Tests Reliable in Idiopathic Inflammatory Myopathies
Patient-performed functional tests were found to be reliable, scalable options for assessing muscle function in idiopathic inflammatory myopathies.